Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ibuprofen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchIbuprofenIbuprofen (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ibuprofen use and clinical outcomes in COVID-19 patients

Rinott et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.06.003
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -21% Improvement Relative Risk Ventilation -12% ICU admission -40% Ibuprofen for COVID-19  Rinott et al.  EARLY TREATMENT Is early treatment with ibuprofen beneficial for COVID-19? Retrospective 403 patients in Israel (March - April 2020) Higher ICU admission with ibuprofen (not stat. sig., p=0.56) c19early.org Rinott et al., Clinical Microbiology a.., Sep 2020 Favorsibuprofen Favorscontrol 0 0.5 1 1.5 2+
Retrospective 403 COVID-19 cases in Israel, showing no significant difference in outcomes with ibuprofen use. Patients were asked about ibuprofen use starting a week before diagnosis of COVID-19 - treatment time may have been early, late, or prophylactic.
Study covers acetaminophen and ibuprofen.
risk of death, 21.1% higher, RR 1.21, p = 0.73, treatment 3 of 87 (3.4%), control 9 of 316 (2.8%).
risk of mechanical ventilation, 11.8% higher, RR 1.12, p = 0.77, treatment 4 of 87 (4.6%), control 13 of 316 (4.1%).
risk of ICU admission, 39.7% higher, RR 1.40, p = 0.56, treatment 5 of 87 (5.7%), control 13 of 316 (4.1%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rinott et al., 30 Sep 2020, retrospective, Israel, peer-reviewed, median age 45.0, 5 authors, study period 15 March, 2020 - 15 April, 2020. Contact: youngsteri@shamir.gov.il.
This PaperIbuprofenAll
Ibuprofen use and clinical outcomes in COVID-19 patients
E Rinott, E Kozer, Y Shapira, A Bar-Haim, I Youngster
Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.06.003
Objective: It was recently suggested that ibuprofen might increase the risk for severe and fatal coronavirus disease 2019 and should therefore be avoided in this patient population. We aimed to evaluate whether ibuprofen use in individuals with COVID-19 was associated with more severe disease, compared with individuals using paracetamol or no antipyretics. Methods: In a retrospective cohort study of patients with COVID-19 from Shamir Medical Centre, Israel, we monitored any use of ibuprofen from a week before diagnosis of COVID-19 throughout the disease. Primary outcomes were mortality and the need for respiratory support, including oxygen administration and mechanical ventilation. Results: The study included 403 confirmed cases of COVID-19, with a median age of 45 years. Of the entire cohort, 44 patients (11%) needed respiratory support and 12 (3%) died. One hundred and seventynine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief. In the ibuprofen group, 3 (3.4%) patients died, whereas in the non-ibuprofen group, 9 (2.8%) patients died (p 0.95). Nine (10.3%) patients from the ibuprofen group needed respiratory support, compared with 35 (11%) from the non-ibuprofen group (p 1). When compared with exclusive paracetamol users, no differences were observed in mortality rates or the need for respiratory support among patients using ibuprofen. Conclusions: In this cohort of COVID-19 patients, ibuprofen use was not associated with worse clinical outcomes, compared with paracetamol or no antipyretic.
Authors' contributions EK and IY conceptualized the study, IY, YS and ABH collected the data, IY and ER conducted the data analyses, ER wrote the first draft of the manuscript, IY and EK revised the manuscript, all authors approved the final version.
References
Day, Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists, BMJ, doi:10.1136/bmj.m1086
Fang, Karakiulakis, Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med, doi:10.1016/S2213-2600(20)30116-8
Little, Non-steroidal anti-inflammatory drugs and covid-19, BMJ, doi:10.1136/bmj.m1185
Shang, Ye, Shi, Wan, Luo et al., Structural basis of receptor recognition by SARS-CoV-2, Nature, doi:10.1038/s41586-020-2179-y
Wan, Shang, Graham, Baric, Li, Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus, J Virol, doi:10.1128/JVI.00127-20
{ 'indexed': {'date-parts': [[2022, 8, 9]], 'date-time': '2022-08-09T22:52:03Z', 'timestamp': 1660085523989}, 'reference-count': 5, 'publisher': 'Elsevier BV', 'issue': '9', 'license': [ { 'start': { 'date-parts': [[2020, 9, 1]], 'date-time': '2020-09-01T00:00:00Z', 'timestamp': 1598918400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 9, 2]], 'date-time': '2021-09-02T00:00:00Z', 'timestamp': 1630540800000}, 'content-version': 'vor', 'delay-in-days': 366, 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 9]]}, 'DOI': '10.1016/j.cmi.2020.06.003', 'type': 'journal-article', 'created': {'date-parts': [[2020, 6, 12]], 'date-time': '2020-06-12T04:46:04Z', 'timestamp': 1591937164000}, 'page': '1259.e5-1259.e7', 'source': 'Crossref', 'is-referenced-by-count': 67, 'title': 'Ibuprofen use and clinical outcomes in COVID-19 patients', 'prefix': '10.1016', 'volume': '26', 'author': [ {'given': 'E.', 'family': 'Rinott', 'sequence': 'first', 'affiliation': []}, {'given': 'E.', 'family': 'Kozer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Y.', 'family': 'Shapira', 'sequence': 'additional', 'affiliation': []}, {'given': 'A.', 'family': 'Bar-Haim', 'sequence': 'additional', 'affiliation': []}, {'given': 'I.', 'family': 'Youngster', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.cmi.2020.06.003_bib1', 'doi-asserted-by': 'crossref', 'first-page': 'm1086', 'DOI': '10.1136/bmj.m1086', 'article-title': 'Covid-19: ibuprofen should not be used for managing symptoms, say ' 'doctors and scientists', 'volume': '368', 'author': 'Day', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.cmi.2020.06.003_bib3', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/S2213-2600(20)30116-8', 'article-title': 'Are patients with hypertension and diabetes mellitus at increased risk ' 'for COVID-19 infection?', 'volume': '8', 'author': 'Fang', 'year': '2020', 'journal-title': 'Lancet Respir Med'}, { 'key': '10.1016/j.cmi.2020.06.003_bib4', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1038/s41586-020-2179-y', 'article-title': 'Structural basis of receptor recognition by SARS-CoV-2', 'volume': '581', 'author': 'Shang', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/j.cmi.2020.06.003_bib5', 'article-title': 'Non-steroidal anti-inflammatory drugs and covid-19', 'volume': '368', 'author': 'Little', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.cmi.2020.06.003_bib10', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/JVI.00127-20', 'article-title': 'Receptor recognition by the novel coronavirus from Wuhan: an analysis ' 'based on decade-long structural studies of SARS coronavirus', 'volume': '94', 'author': 'Wan', 'year': '2020', 'journal-title': 'J\xa0Virol'}], 'container-title': 'Clinical Microbiology and Infection', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1198743X20303438?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1198743X20303438?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 11, 4]], 'date-time': '2021-11-04T00:52:55Z', 'timestamp': 1635987175000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1198743X20303438'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9]]}, 'references-count': 5, 'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2020, 9]]}}, 'alternative-id': ['S1198743X20303438'], 'URL': 'http://dx.doi.org/10.1016/j.cmi.2020.06.003', 'relation': {}, 'ISSN': ['1198-743X'], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'Clinical Microbiology and Infection', 'published': {'date-parts': [[2020, 9]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit